SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently facing a sharp sell-off driven by a confluence of negative sentiment, including a federal jury finding that Elon Musk defrauded Twitter shareholders and concerns regarding broader macroeconomic instability. The community is deeply divided, with bears pointing to falling delivery numbers and operational scrutiny as evidence of a structural decline, while loyal bulls continue to highlight upcoming projects like TeraFab and the potential for a rebound as reasons to maintain their positions.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy is trending as investors debate the long-term potential of the project, with many in the community expressing unwavering patience for a future breakout despite current price volatility. Supporters are actively highlighting the project's utility and health-focused mechanics, often drawing comparisons to historical market recoveries to justify their continued accumulation.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is experiencing significant volatility as investors debate the impact of the Kodiak Building Partners acquisition alongside ongoing concerns regarding share dilution and macro headwinds in the construction sector. While some community members remain bullish on Brad Jacobs' long-term consolidation strategy and anticipated acquisition pipeline, others are expressing frustration over the recent downward price pressure and uncertainty surrounding the integration timeline.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR is trending as investors focus on its integration into the AI-native economy, with community discussion highlighting its role in chain abstraction, privacy-focused protocols, and recent infrastructure developments. Many are closely watching the balance between retail accumulation and institutional activity while expressing optimism about its long-term utility in the decentralized AI landscape.

KKR & Co., Inc. operates as an investment firm. It offers alternative asset management as well as capital markets and insurance solutions. The firm's business segments include Asset Management and Insurance Business. The Asset Management segment engages in providing private equity, real assets, credit and liquid strategies, capital markets, and principal activities. The Insurance Business segment offers retirement, life insurance and reinsurance solutions to clients across individual and institutional markets. The company was founded by Henry Kravis, George R. Roberts, and Jerome Kholberg on May 1, 1976 and is headquartered in New York, NY.

KKR & Co. Inc

KKR & Co. Inc.

KKR is actively being discussed as a major player in the private credit and infrastructure space, with investors noting a positive trend following record fee-related earnings and significant capital raising milestones. The community remains focused on KKR's ongoing pivot toward permanent capital and wealth management, viewing the stock as a compelling long-term play despite broader market volatility and questions surrounding the liquidity of private markets.

LayerX is a web3 infrastructure and innovation ecosystem focused on helping builders go from idea to real, sustainable products. The platform connects hackathons, developer tools, incubation programs, and community-driven ecosystems under a single framework. LayerX supports both technical and non-technical participants by providing access to mentorship, partnerships, hackathons, onchain tasks, and more.  Its products enable teams to prototype, validate, and scale projects while aligning incentives between builders, communities, and partners. The LX token acts as the shared economic layer across the ecosystem, supporting participation, staking, governance, and access to ecosystem features.

LayerX

LayerX, formerly known as Bepro, is drawing significant community interest as investors discuss its low market capitalization, potential for long-term growth, and recent developments within its ecosystem. Supporters are actively sharing bullish perspectives on the project's utility and future potential while tracking technical indicators and looking for signs of broader adoption.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is trending as investors capitalize on its recent NYSE listing, which provides rare public market access to high-profile private AI and tech companies like Anthropic, OpenAI, and SpaceX. While the community is actively debating the significant premium over the fund's net asset value and the impact of a six-month lockup on available float, many are focused on the stock's high volatility and potential for momentum-driven price swings.

Blackstone, Inc. engages in the provision of investment and fund management services. It operates through the following segments: Real Estate, Private Equity, Credit and Insurance, and Hedge Fund Solutions. The Real Estate segment includes management of opportunistic real estate funds, Core+ real estate funds, high-yield real estate debt funds, and liquid real estate debt funds. The Private Equity segment consists of management of flagship corporate private equity funds, sector and geographically focused corporate private equity funds, core private equity funds, an opportunistic investment platform, a secondary fund of funds business, infrastructure-focused funds, a life sciences investment platform, a growth equity investment platform, a multi-asset investment program for eligible high net worth investors and a capital markets services business. The Credit and Insurance segment refers to Blackstone Credit, which is organized into two overarching strategies: private credit which includes mezzanine direct lending funds, private placement strategies, stressed and distressed strategies and energy strategies, and liquid credit which consists of CLOs, closed-ended funds, open ended funds and separately managed accounts. In addition, the segment includes an insurer-focused platform, an asset-based finance platform, and publicly traded master limited partnership investment platform. The Hedge Fund Solutions segment focuses on Blackstone Alternative Asset Management, which manages a broad range of commingled and customized hedge fund of fund solutions. It also includes a GP Stakes business and investment platforms that invest directly, as well as investment platforms that seed new hedge fund businesses and create alternative solutions through daily liquidity products. The company was founded by Stephen Allen Schwarzman in 1985 and is headquartered in New York, NY.

Blackstone Inc

Blackstone shares are under pressure as investors react to mixed signals regarding private credit exposure and shifting regulatory landscapes, despite the firm reporting a significant earnings beat and record assets under management. Market participants are actively debating whether the recent dip represents a buying opportunity in a high-growth financial leader or a warning sign of broader systemic risks within the alternative asset sector.

Lam Research Corp. engages in the design, manufacture, marketing, refurbishment, and provision of semiconductor processing equipment used in the fabrication of integrated circuits. It operates through the following geographical segments: United States, China, Europe, Japan, Korea, Southeast Asia and Taiwan. The company was founded by David K. Lam in 1980 and is headquartered in Fremont, CA.

Lam Research Corp.

Lam Research is currently capturing significant market interest as it benefits from surging demand for AI-driven chip fabrication equipment, with community members actively monitoring its strong relative strength against industry peers. Investors are closely tracking upcoming earnings while debating the stock's valuation and potential upside against the backdrop of broader semiconductor sector consolidation.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

Amarin is trending as community discussions center on the Supreme Court's potential involvement in its patent infringement case against Hikma, following the Solicitor General's filing. Investors are also closely monitoring the upcoming EMT2 trial results and potential M&A activity as the company continues its restructuring and cost-cutting initiatives.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced multiple abstracts have been...

Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI FAKZYNJA (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Womens Cancers

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced it will present new long-term...

Foresite Capital Management VI LLC Has $23.09 Million Holdings in Verastem, Inc. $VSTM

Foresite Capital Management VI LLC increased its stake in shares of Verastem, Inc. (NASDAQ:VSTM - Free Report) by 104.9% during the third quarter, according to its most recent Form 13F filing with...

Verastem's (VSTM) Buy Rating Reaffirmed at BTIG Research

BTIG Research reissued a "buy" rating and set a $19.00 target price on shares of Verastem in a research note on Thursday...

Wall Street Analysts See a 159.31% Upside in Verastem (VSTM): Can the Stock Really Move This High?

The mean of analysts' price targets for Verastem (VSTM) points to a 159.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Jefferies Financial Group Inc. Increases Stake in Verastem, Inc. $VSTM

Jefferies Financial Group Inc. increased its stake in Verastem, Inc. (NASDAQ:VSTM - Free Report) by 48.4% in the third quarter, according to its most recent 13F filing with the Securities & Exchange...

Verastem (NASDAQ:VSTM) Raised to Hold at Wall Street Zen

Wall Street Zen upgraded Verastem from a "sell" rating to a "hold" rating in a report on Saturday...

Verastem, Inc. (NASDAQ:VSTM) Receives Average Recommendation of "Moderate Buy" from Brokerages

Verastem, Inc. (NASDAQ:VSTM - Get Free Report) has received a consensus rating of "Moderate Buy" from the ten analysts that are presently covering the company, Marketbeat.com reports. One analyst has...

<ul class="summary-bullets"><li>The company's Q4 adjusted loss was $0.48 per share, while revenue of $17.5 million beat expectations of $16.84 million.</li><li>Avmapki Fakzynja co-pack generated $17.5 million in Q4 revenue and $30.9 million in 2025 following FDA approval in May.</li><li>The KRAS cancer drug VS-7375 cleared multiple dose levels with no safety issues.</li></ul>Shares of Verastem, Inc. (VSTM) rose nearly 3% in after-hours trading on Wednesday, even after the cancer drug developer reported a quarterly earnings miss, as investors focused on early traction from its newly approved ovarian cancer therapy and a string of upcoming clinical milestones.<a href="https://stocktwits.com/symbol/VSTM">VSTM stock</a> jumped over 2% in Wednesday’s regular session.<h2 class="st-heading-2">VSTM Q4 Review</h2>The company reported an adjusted loss of $0.48 per share for the fourth quarter (Q4), slightly wider than analysts’ $0.50-per-share loss estimate, while revenue came in at $17.5 million, topping the $16.84 million consensus estimate.Revenue in the quarter was driven by sales of Avmapki Fakzynja co-pack, a combination therapy approved by the U.S. Food and Drug Administration (FDA) in May 2025 for patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC).The therapy generated $17.5 million in net product revenue in Q4 and $30.9 million for the full year, marking the company’s first full year of commercial revenue from the drug following its accelerated approval.“2025 was a transformative year for us, highlighted by the landmark FDA approval of Avmapki Fakzynja co-pack,” CEO Dan Paterson said, adding that the treatment is seeing “positive response across the LGSOC community with gynecologic and medical oncologists.”Verastem ended 2025 with $205 million in cash, cash equivalents, and investments. The company said funds will support operations into the first half of 2027.<h2 class="st-heading-2">VS-7375 Cancer Drug Advances In Early Trials</h2>Investors also focused on updates related to VS-7375, Verastem’s oral KRAS G12D inhibitor being developed for solid tumors.The company said the therapy has cleared multiple dose levels in early studies with no dose-limiting toxicities, allowing dose escalation to continue to 1,200 mg once daily. A 600 mg daily dose in combination with Cetuximab, a form of cancer therapy, has also been cleared without safety concerns, with higher dose levels now being evaluated.Following feedback from the FDA, Verastem said it plans to pursue Phase 2 registration-directed studies for VS-7375 in several cancer indications, including second-line pancreatic ductal adenocarcinoma, second or third-line non-small cell lung cancer, and later-line colorectal cancer in combination with Cetuximab.<h2 class="st-heading-2">Verastem Flags Multiple Pipeline Catalysts</h2>Verastem outlined several upcoming milestones that could drive investor interest in the months ahead. The company expects to report early clinical data from the VS-7375-101 study in the first half of 2026 and select the recommended Phase 2 dose with Cetuximab, allowing it to begin a colorectal cancer combination expansion cohort later in the first half of 2026.Enrollment in combination dose-escalation cohorts is expected to be completed by mid-2026, while monotherapy expansion cohorts are projected to finish enrollment in the second half of 2026. The company also plans to select the recommended Phase 2 dose and begin pancreatic and lung cancer combination expansion cohorts in the second half of the year.Separately, Verastem said it plans to present updated data from the Ramp 201 trial of Avmapki Fakzynja at the Society of Gynecologic Oncology annual meeting in April, while longer-term development continues through the Ramp 301 Phase 3 trial, which is expected to report a topline primary endpoint readout in mid-2027.The company is also preparing an update on the Ramp 205 study, which evaluates the therapy in combination with chemotherapy for first-line metastatic pancreatic cancer, with results expected in the second quarter of 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for VSTM was ‘extremely bullish’ amid a 450% surge in 24-hour message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/vstm_ss_png_aa5fb80917.webp" alt="vstm ss.png" width="962" height="136"><figcaption>VSTM sentiment and message volume as of March 4 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/CrozrX/message/646623324">said</a>, “Phenomenal safety with VS-7375 and as a bonus, all resolved quickly!!”<stembedurl>https://stocktwits.com/CrozrX/message/646623324</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Universaal/message/646621923">said</a> they “like what I heard this is going $7 plus tomorrow”<stembedurl>https://stocktwits.com/Universaal/message/646621923</stembedurl>VSTM stock has declined 25% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Verastem Oncology logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Did Verastem Stock Jump After-Hours Despite An Earnings Miss?

The company flagged several catalysts ahead, including early VS-7375 data in the first half of the year, and Ramp 205 pancreatic cancer study results in Q2.

Equity

Verastem Q4 Earnings Call Highlights

Verastem (NASDAQ:VSTM) executives said the company's transition to a commercial-stage business accelerated in 2025 following FDA approval of AVMAPKI FAKZYNJA CO-PACK, the first treatment specifically...

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.45	--	--	N/A
Q4 '25	-$0.52	-$0.39	25.36%	BEAT
Q3 '25	-$0.62	-$1.35	-117.35%	MISSED
Q2 '25	-$0.73	-$0.39	46.41%	BEAT
Q1 '25	-$0.70	-$0.96	-37.14%	MISSED

VSTM
Verastem Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest VSTM News

VSTMVerastem Inc